TransCode Therapeutics Inc. (NASDAQ:RNAZ) Short Interest Down 34.8% in July

TransCode Therapeutics Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 34,446 shares, a decrease of 34.8% from the June 30th total of 52,823 shares. Based on an average daily trading volume, of 41,287 shares, the days-to-cover ratio is presently 0.8 days. Currently, 3.3% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Get TransCode Therapeutics alerts:

Check Out Our Latest Stock Report on RNAZ

TransCode Therapeutics Stock Performance

TransCode Therapeutics stock opened at $5.25 on Friday. TransCode Therapeutics has a one year low of $3.82 and a one year high of $20.99. The company has a 50-day simple moving average of $6.35 and a 200-day simple moving average of $8.02. The firm has a market capitalization of $5.57 million, a P/E ratio of -0.10 and a beta of 1.23.

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($21.28) earnings per share for the quarter.

TransCode Therapeutics Company Profile

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.

Further Reading

• Five stocks we like better than TransCode Therapeutics
• Everyone’s Focused on China—But That’s Not ASML’s Biggest Risk
• Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
• L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
• Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.